Kura Oncology (KURA) CMO sells 8,180 shares for RSU tax cover

Rhea-AI Filing Summary

Kura Oncology Chief Medical Officer Mollie Leoni reported routine share sales tied to tax withholding on restricted stock units (RSUs). On January 27, 2026, she sold a total of 8,180 shares of Kura Oncology common stock at $8.4607 per share in four transactions classified as "sell-to-cover" for RSU vesting taxes.

After these sales, Leoni directly beneficially owned 267,274 shares of Kura Oncology common stock, indicating she retains a substantial equity position while satisfying tax obligations from prior RSU awards.

Insider Trade Summary

Net Seller: 8,180 shares ($69,209)

Net Sell 4 txns

Insider Leoni Mollie

Role Chief Medical Officer

Sold 8,180 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,655	$8.4607	$31K
Sale	Common Stock	2,233	$8.4607	$19K
Sale	Common Stock	951	$8.4607	$8K
Sale	Common Stock	1,341	$8.4607	$11K

Holdings After Transaction: Common Stock — 271,799 shares (Direct)

Footnotes (1)

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/24. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leoni Mollie

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		3,655	D(1)	$8.4607	271,799	D
Common Stock	01/27/2026		S		2,233	D(2)	$8.4607	269,566	D
Common Stock	01/27/2026		S		951	D(3)	$8.4607	268,615	D
Common Stock	01/27/2026		S		1,341	D(4)	$8.4607	267,274	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25.

2. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/24.

3. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.

4. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.

	Teresa Bair, Attorney-in-fact for Mollie Leoni	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kura Oncology (KURA) insider Mollie Leoni report in this Form 4?

Mollie Leoni, Kura Oncology’s Chief Medical Officer, reported selling shares of common stock on January 27, 2026. The transactions were routine sell-to-cover sales to pay taxes triggered by the vesting of previously granted restricted stock units.

How many Kura Oncology shares did Mollie Leoni sell on January 27, 2026?

On January 27, 2026, Mollie Leoni sold a total of 8,180 Kura Oncology common shares. The sales occurred in four separate transactions, all at a price of $8.4607 per share, and were executed solely to cover tax liabilities from RSU vesting.

What was the sale price of Kura Oncology (KURA) shares in Leoni’s Form 4?

All reported Kura Oncology share sales by Mollie Leoni were executed at $8.4607 per share. Each transaction involved common stock sold on January 27, 2026, in connection with tax withholding for vesting restricted stock unit awards previously granted to her.

How many Kura Oncology shares does Mollie Leoni own after these transactions?

Following the reported transactions, Mollie Leoni beneficially owned 267,274 shares of Kura Oncology common stock. This post-transaction balance reflects her remaining direct holdings after selling 8,180 shares to satisfy tax obligations arising from vested restricted stock units.

Were Mollie Leoni’s Kura Oncology share sales discretionary or tax-related?

The filing states Leoni’s Kura Oncology share sales were sell-to-cover transactions for taxes. Each sale was tied to RSUs that vested from awards dated 1/2/25, 1/26/24, 2/16/23, and 1/26/22, indicating the purpose was to satisfy withholding obligations.

What is Mollie Leoni’s role at Kura Oncology (KURA) mentioned in the Form 4?

The Form 4 identifies Mollie Leoni as an officer of Kura Oncology serving as Chief Medical Officer. Her position as an executive officer requires reporting changes in her ownership of Kura Oncology common stock under Section 16 of the Securities Exchange Act.